Drug intelligence / Profile preview

BWV-302

Development stage: Preclinical
Lead developer: Onconetix
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

BWV-302 is a **malaria vaccine candidate** under development by Blue Water Vaccines. It is designed as a **virus-like particle (VLP)–based vaccine** that utilizes the company's S&P (shell and protrusion) platform technology, combining norovirus antigens with malaria antigens. The vaccine aims to induce protective immunity against malaria, leveraging the immunogenicity of the VLP platform to enhance the response to malaria-specific antigens. Development is preclinical, and no information on clinical trial completion or human efficacy is available at this time[4][7][10][13][19][24].

Beyond the preview

Go deeper on BWV-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWV-302.

Explore the full profile